An FMR1 premutation is a particular size of CGG repeat expansion in the FMR1 gene. It is not the same result as a fragile X full mutation, and it is not a prediction that someone will inevitably become ill. Reading the report means separating three questions: what the laboratory measured, what it may mean for the person tested, and what could happen when the repeat is passed to a child.

Start with the repeat result

FMR1 contains a repeated CGG sequence in its untranslated region. Laboratories usually describe fewer than 45 repeats as normal, 45–54 as intermediate, approximately 55–200 as a premutation, and more than 200 as a full mutation. Boundaries need the laboratory’s measurement uncertainty and, where relevant, methylation and mosaicism assessment. A result close to a boundary should not be reclassified by rounding it yourself. GeneReviews: FMR1 disorders.

FMR1 makes FMRP, a protein involved in regulating how other proteins are produced. Full mutations commonly involve methylation and reduced gene activity; a premutation has different biological consequences. The word “pre” does not mean that a person’s premutation will inevitably turn into fragile X syndrome as they get older. MedlinePlus Genetics: FMR1.

What can a premutation mean for health?

Some people remain well. Others develop a fragile X-associated condition. FXPOI involves ovarian insufficiency before age 40; FXTAS is a later-life neurological disorder that can involve intention tremor, balance problems and cognitive changes. Neither is diagnosed by a repeat count alone. New symptoms deserve their own clinical assessment, including other possible causes. CDC overview of associated disorders.

For someone with ovaries, a premutation can justify a conversation about menstrual changes, reproductive goals and when specialist advice would be useful. It does not establish infertility. Ovarian function and pregnancy possibilities vary, including after a diagnosis of ovarian insufficiency. NICHD: fragile X-associated primary ovarian insufficiency.

Transmission and expansion are different probabilities

A woman with one premutation-bearing X chromosome has a 50% chance of passing that X to each child. The chance that the transmitted repeat expands to a full mutation is a separate question. Repeat length and AGG interruptions help inform maternal transmission counselling. A man with a premutation passes his X to daughters, not sons; paternal transmission usually does not produce a full mutation. These patterns should be explained using the actual family results rather than a generic risk percentage. Inheritance and counselling in GeneReviews.

For a woman with one premutation-bearing X, each pregnancy has a 50% chance of inheriting that X. Expansion risk conditional on transmission depends on the repeat and other factors; it is not a fixed 50%.
For a woman with one premutation-bearing X, each pregnancy has a 50% chance of inheriting that X. Expansion risk conditional on transmission depends on the repeat and other factors; it is not a fixed 50%.

Open full-size illustration (new tab)

AGG interruptions interrupt an otherwise repetitive tract. In a transmission study, they helped explain differences in repeat stability beyond repeat size alone. They do not eliminate uncertainty, change the basic chance of inheriting the X chromosome, or reliably predict who will develop FXPOI or FXTAS. Yrigollen and colleagues: AGG interruptions and maternal transmission.

Two practical examples

Fictional example: a screening result with 68 repeats. Leila feels well and asks whether this means she has fragile X syndrome. Her counsellor first confirms the report’s category and assay, then discusses her own health separately from reproductive risk. If pregnancy planning is relevant, they ask whether AGG information would improve the estimate of expansion risk. A relative’s experience is useful family history, but it is not a substitute for her own result.

Fictional example: a premutation and a new tremor. David has a known premutation and develops shaking in his late sixties. The result makes FXTAS a consideration; it does not exclude essential tremor, medication effects or another neurological condition. The useful next step is a clinical evaluation with the laboratory report available, not a diagnosis from a search-engine symptom list.

Check what the test could measure

A routine exome result should not be assumed to exclude an FMR1 expansion. Ask whether repeat sizing was performed, whether the method can detect large expansions and mosaicism, and when methylation testing is needed. The ACMG laboratory standard explains why different methods provide different information. ACMG fragile X testing standard, 2021.

A short appointment worksheet

  1. Copy the exact repeat sizes, category, method and any uncertainty from the report.
  2. Record why testing was done and which relatives have documented results.
  3. Separate current symptoms from future health concerns and pregnancy questions.
  4. Ask whether AGG analysis, methylation analysis or another method would answer an unresolved question.
  5. Agree who will communicate family implications, with consent, and what follow-up is actually needed.

For background, read what repeat-expansion tests can miss, penetrance and variable expression, and testing relatives for a known familial finding. Use the genetics-care directory to locate appropriate counselling services.